IDH1 and acute myeloid leukemia: In a phase 1 trial in patients with IDH1-mutated AML, ivosidenib was initiated 30–90 days following HSCT; the two-year CIR of relapse was 19%, and non-relapse mortality was 0%, with two-year PFS 81% and two-year OS 88% [104].